Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03710538
Other study ID # SNACK_CF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2019
Est. completion date December 31, 2022

Study information

Verified date April 2023
Source Institut de Recherches Cliniques de Montreal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to test the feasibility and effectiveness of a pre-meal snack to reduce the postprandial glycemia (PPG) excursion after a breakfast consumption in adult patients with cystic fibrosis (CF). The investigators also want to investigate the impact of a postprandial exercise to reduce the PPG excursion. An improvement in PPG excursions can improve the condition of CF patients primarily by delaying the onset of cystic fibrosis related diabetes (CFRD) and / or by reducing the risk of lung function loss.


Description:

The investigators are proposing a randomized pilot study to explore the impact of a soy beverage of carbohydrates and protein early in the morning, to stimulate and initiate secretion of Insulin to reduce PPG excursions of the following a lunch in adult patients with CF. Investigators will also study the impact of a post meal exercise on the PPG excursion. Fourteen participants will be included and will each perform a 4-hour intervention in cross over design according to those 4 following experimental conditions: 1. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study [condition control] 2. Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study [snack effect on PPG excursion] 3. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5); [exercise effect on the PPG excursion] 4. Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5). [Combined snack and exercise effect on the PPG excursion] Main result: plasma glucose area under the curve. The underlying mechanisms, insulin, incretin hormones (GLP-1 and GIP), acceptability and side effects (mealtime hyperglycaemia) should also be measured. At the end of this pilot project, the investigators will have established a pre-meal snack and/ or postprandial exercise have a positive impact on PPG.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 31, 2022
Est. primary completion date May 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of cystic fibrosis, - Be over 18 years old. Exclusion Criteria: - Pharmacological treatment for cystic fibrosis related diabetes. - Signs of secondary infection: the test will be practiced at least 1 month after the end of infection treatment - People with severe gastrointestinal illness (Crohn's disease, celiac disease and a recent history (<1 year) of bowel obstruction). - Allergy to one of the ingredients of the menu (example: celiac disease) - According to the judgment of the investigator, medications or conditions that could interfere with glucose metabolism (eg: oral steroids) - Pregnancy in progress - Corrector or potentiator prescribed whose dose is not stable the last 2 months.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Snack beverage
Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
Behavioral:
Exercise
3min walk at 60% VO2max every 30 minutes,(x5)

Locations

Country Name City State
Canada Institut de Recherches Cliniques de Montréal (IRCM) Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Institut de Recherches Cliniques de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total area under the curve for plasma glucose Overall study period (4 hours)
Secondary Area under the curve for plasma glucose From start of study to breakfast time (1 hour)
Secondary Area under the curve for plasma glucose From time of breakfast to the end of the study (3 hours)
Secondary Total area under the curve for insulin Overall study period (4 hours)
Secondary Area under the curve for insulin From start of study to breakfast time (1 hour)
Secondary Area under the curve for insulin From breakfast time to the end of the study (3 hours)
Secondary Mean plasma glucose Overall study period (4 hours)
Secondary Mean insulin Overall study period (4 hours)
Secondary Percentage of time with plasma glucose concentration above 8.0 mmol/L Overall study period (4 hours)
Secondary Percentage of time with plasma glucose concentration above 10.0 mmol/L Overall study period (4 hours)
Secondary Percentage of time with plasma glucose concentration above 11.0 mmol/L Overall study period (4 hours)
Secondary Percentage of time with plasma glucose concentration below 4.0 mmol/L Overall study period (4 hours)
Secondary Post-breakfast peak plasma glucose 1 hour after breakfast
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A